Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers

被引:0
|
作者
Chen, Yao-Tseng [1 ]
Ross, Dara S. [1 ]
Chiu, Rita [2 ]
Zhou, Xi K. [3 ]
Chen, Yunn-Yi [4 ]
Lee, Peishan [2 ]
Hoda, Syed A. [1 ]
Simpson, Andrew J. [2 ]
Old, Lloyd J. [2 ]
Caballero, Otavia [2 ]
Neville, A. Munro [2 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA
[2] Ludwig Inst Canc Res, New York Branch, New York, NY USA
[3] Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY 10021 USA
[4] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA
来源
PLOS ONE | 2011年 / 6卷 / 03期
关键词
T-CELL RESPONSES; NY-ESO-1; EXPRESSION; PROTEIN EXPRESSION; ANTIBODY; IMMUNOGENICITY; IDENTIFICATION; CARCINOMA; FAMILY; GENES; CT45;
D O I
10.1371/journal.pone.0017876
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Cancer/testis (CT) antigens are protein antigens normally expressed only in germ cells of testis, and yet are expressed in a proportion of a wide variety of human cancers. CT antigens can elicit spontaneous immune responses in cancer patients with CT-positive cancers, and CT antigen-based therapeutic cancer vaccine trials are ongoing for "CT-rich" tumors. Although some previous studies found breast cancer to be "CT-poor", our recent analysis identified increased CT mRNA transcripts in the ER-negative subset of breast cancer. Methodology/Principal Findings: In this study, we performed a comprehensive immunohistochemical study to investigate the protein expression of eight CT genes in 454 invasive ductal carcinomas, including 225 ER/PR/HER2-negative (triple-negative) carcinomas. We found significantly more frequent expression of all eight CT antigens in ER-negative cancers, and five of them-MAGEA, CT7, NY-ESO-1, CT10 and CT45, were expressed in 12-24% of ER-negative cancers, versus 2-6% of ER-positive cancers (p < 0.001 to 0.003). In comparison, GAGE, SAGE1 and NXF2 were only expressed in 3-5% of ER-negative and 0-2% of ER-positive cancers. ER-negative cancers were also more likely to simultaneously co-express multiple CT antigens, with 27% (34/125) of ER-negative, CT-positive tumors expressing three or more CT antigens. HER2 status had no consistent effect on CT expression, and triple-negative carcinomas showed similar frequencies of MAGEA and NY-ESO-1 expression as ER-negative/HER2-positive carcinomas. More frequent CT expression was also found in tumors with higher nuclear grade (p < 0.001 to p = 0.01) and larger in size (> 2 cm). Conclusions/Significance: CT antigens are preferentially expressed in hormone receptor-negative and high-grade breast cancer. Considering the limited treatment options for ER/PR/HER2 triple-negative breast cancer, the potential of CT-based immunotherapy should be explored.
引用
收藏
页数:9
相关论文
共 25 条
  • [1] Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome
    Campbell, Michael J.
    Tonlaar, Nathan Y.
    Garwood, Elisabeth R.
    Huo, Dezheng
    Moore, Dan H.
    Khramtsov, Andrey I.
    Au, Afred
    Baehner, Frederick
    Chen, Yinghua
    Malaka, David O.
    Lin, Amy
    Adeyanju, Oyinlolu O.
    Li, Shihong
    Gong, Can
    McGrath, Michael
    Olopade, Olufunmilayo I.
    Esserman, Laura J.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (03) : 703 - 711
  • [2] Role of Renin-Angiotensin-System in Human Breast Cancer Cells: Is There a Difference in Regulation of Angiogenesis between Hormone-Receptor Positive and Negative Breast Cancer Cells?
    Herr, Daniel
    Sauer, Christof
    Holzheu, Iris
    Sauter, Regina
    Janni, Wolfgang
    Woeckel, Achim
    Wulff, Christine
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (06) : 626 - 634
  • [3] Distinguishing medullary carcinoma of the breast from high-grade hormone receptor-negative invasive ductal carcinoma: an immunohistochemical approach
    Flucke, Uta
    Flucke, Maria Theresia
    Hoy, Ludwig
    Breuer, Elisabeth
    Goebbels, Rolf
    Rhiem, Kerstin
    Schmutzler, Rita
    Winzenried, Helene
    Braun, Michael
    Steiner, Susanne
    Buettner, Reinhard
    Gevensleben, Heidrun
    HISTOPATHOLOGY, 2010, 56 (07) : 852 - 859
  • [4] High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers
    Tokunaga, Eriko
    Okada, Satoko
    Yamashita, Nami
    Akiyoshi, Sayuri
    Kitao, Hiroyuki
    Morita, Masaru
    Kakeji, Yoshihiro
    Maehara, Yoshihiko
    BREAST CANCER, 2012, 19 (02) : 161 - 169
  • [5] SPONTANEOUS PATHOLOGICAL COMPLETE REGRESSION OF HIGH-GRADE TRIPLE-NEGATIVE BREAST CANCER WITH AXILLARY METASTASIS
    Cserni, Gabor
    Serfozo, Orsolya
    Ambrozay, Eva
    Marko, Laszlo
    Krenacs, Laszlo
    POLISH JOURNAL OF PATHOLOGY, 2019, 70 (02) : 139 - 143
  • [6] Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers
    Feng, Zheng
    Wen, Hao
    Ju, Xingzhu
    Bi, Rui
    Chen, Xiaojun
    Yang, Wentao
    Wu, Xiaohua
    ONCOTARGET, 2017, 8 (20) : 32848 - 32855
  • [7] MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas
    Mengus, Chantal
    Schultz-Thater, Elke
    Coulot, Julie
    Kastelan, Zeljko
    Goluza, Eleonora
    Coric, Marijana
    Spagnoli, Giulio C.
    Hudolin, Tvrtko
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (10) : 2459 - 2463
  • [8] Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers
    Raghavendra, Ashwini
    Kalita-de Croft, Priyakshi
    Vargas, Ana C.
    Smart, Chanel E.
    Simpson, Peter T.
    Saunus, Jodi M.
    Lakhani, Sunil R.
    HISTOPATHOLOGY, 2018, 73 (01) : 68 - 80
  • [9] Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer
    Wang, Kang
    Li, Lun
    Franch-Exposito, Sebastia
    Le, Xin
    Tang, Jun
    Li, Qing
    Wu, Qianxue
    Bassaganyas, Laia
    Camps, Jordi
    Zhang, Xiang
    Li, Hongyuan
    Foukakis, Theodoros
    Xiang, Tingxiu
    Wu, Jiong
    Ren, Guosheng
    MOLECULAR ONCOLOGY, 2022, 16 (12) : 2413 - 2431
  • [10] A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression
    Feng, Zheng
    Wen, Hao
    Bi, Rui
    Ju, Xingzhu
    Chen, Xiaojun
    Yang, Wentao
    Wu, Xiaohua
    SCIENTIFIC REPORTS, 2016, 6